5.205
Schlusskurs vom Vortag:
$5.19
Offen:
$5.15
24-Stunden-Volumen:
163.66K
Relative Volume:
0.22
Marktkapitalisierung:
$387.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-9.2946
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
+7.32%
1M Leistung:
+16.97%
6M Leistung:
+24.22%
1J Leistung:
+25.42%
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CRVS
Corvus Pharmaceuticals Inc
|
5.205 | 396.41M | 0 | -27.03M | -23.97M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
604.87 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
465.72 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
667.34 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
310.73 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
2021-12-01 | Fortgesetzt | Jefferies | Buy |
2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
2019-09-12 | Eingeleitet | Mizuho | Buy |
2019-05-29 | Eingeleitet | ROTH Capital | Buy |
2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
Price momentum metrics for Corvus Pharmaceuticals Inc. explainedWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
Is Corvus Pharmaceuticals Inc. the Top Chart Pick This WeekJuly 2025 Reactions & Verified Short-Term Trading Plans - newsyoung.net
Pattern recognition hints at Corvus Pharmaceuticals Inc. upsideEarnings Overview Summary & Fast Momentum Stock Entry Tips - Newser
Corvus Pharmaceuticals Inc. stock volume spike explained2025 Technical Patterns & Entry and Exit Point Strategies - Newser
How to read the order book for Corvus Pharmaceuticals Inc.Market Trend Report & Capital Efficiency Focused Strategies - Newser
Can volume confirm reversal in Corvus Pharmaceuticals Inc.2025 Investor Takeaways & Daily Stock Trend Watchlist - Newser
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.July 2025 Summary & Daily Technical Stock Forecast Reports - Newser
Analyzing recovery setups for Corvus Pharmaceuticals Inc. investors2025 Biggest Moves & Long-Term Investment Growth Plans - Newser
Will Corvus Pharmaceuticals Inc. benefit from macro trendsQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Comparing Corvus Pharmaceuticals Inc. in custom built stock radarsLong Setup & Weekly High Return Stock Opportunities - Newser
Corvus Pharmaceuticals Inc. stock trend forecastJuly 2025 EndofMonth & Long-Term Safe Investment Ideas - Newser
Is Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Trading At A 49% Discount? - simplywall.st
Is this a good reentry point in Corvus Pharmaceuticals Inc.July 2025 Market Mood & Verified Technical Trade Signals - Newser
Is Corvus Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - Newser
What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysJuly 2025 Recap & Daily Price Action Insights - Newser
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesTrade Exit Report & Fast Exit Strategy with Risk Control - Newser
Is Corvus Pharmaceuticals Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.July 2025 EndofMonth & Reliable Trade Execution Plans - Newser
Real time pattern detection on Corvus Pharmaceuticals Inc. stockEarnings Beat & Target Return Focused Picks - Newser
Live market analysis of Corvus Pharmaceuticals Inc.Rate Cut & Safe Capital Growth Stock Tips - Newser
Price action breakdown for Corvus Pharmaceuticals Inc.July 2025 Fed Impact & Safe Investment Capital Preservation Plans - Newser
Can swing trading help recover from Corvus Pharmaceuticals Inc. losses2025 Market Outlook & Stepwise Entry and Exit Trade Signals - Newser
Corvus Pharmaceuticals’ Earnings Call Highlights Progress - MSN
Is now a turning point for Corvus Pharmaceuticals Inc.2025 Year in Review & Risk Managed Investment Entry Signals - Newser
New Product Launches: Will They Boost Corvus Pharmaceuticals Inc. Stock in 2025July 2025 Intraday Action & Daily Profit Focused Screening - Newser
Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Volume & Daily Growth Stock Tips - Newser
Is Corvus Pharmaceuticals Inc. in a long term uptrendJuly 2025 Action & Consistent Profit Focused Trading Strategies - thegnnews.com
Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com
A Tale of Resilience: Corvus Pharmaceuticals Inc Amid Stock Market Turbulence - investchronicle.com
How Resilient Is Corvus Pharmaceuticals Inc. Stock During Economic DownturnsEarnings Risk Report & High Yield Stock Recommendations - Newser
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corvus Pharmaceuticals Inc-Aktie (CRVS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Thompson Peter A. | Director |
Jun 27 '25 |
Sale |
4.16 |
1,176,332 |
4,891,894 |
7,165,006 |
Jones William Benton | See Remarks |
Jun 04 '25 |
Option Exercise |
3.50 |
19,357 |
67,750 |
173,130 |
MILLER RICHARD A MD | President and CEO |
May 07 '25 |
Option Exercise |
3.50 |
559,073 |
1,956,756 |
1,136,707 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):